Thermosensitive In situ Gelling System for Dermal Drug Delivery of Rutin

Sefa Gözcü; Kerem Heybet Polat

doi:10.4274/tjps.galenos.2022.00334

Thermosensitive In situ Gelling System for Dermal Drug Delivery of Rutin

Turk J Pharm Sci. 2023 May 9;20(2):78-83. doi: 10.4274/tjps.galenos.2022.00334.

Authors

Sefa Gözcü¹, Kerem Heybet Polat²

Affiliations

¹ Erzincan Binali Yıldırım University, Faculty of Pharmacy, Department of Pharmacognosy, Erzincan, Türkiye.
² Erzincan Binali Yıldırım University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Erzincan, Türkiye.

Abstract

Objectives: Rutin has been broadly applied for treating several diseases due to its pharmacological activities. However, its low aqueous solubility limits its absorption and bioavailability. This research aims to increase the solubility of rutin using cyclodextrin and to develop a temperature-triggered in situ gelling system for dermal application.

Materials and methods: The solubility of rutin was increased with sulfobutyl ether-β-cyclodextrin (SBE-β-CD). Rutin- SBE-β-CD inclusion complex was prepared by kneading and freeze dying method. Structural characterization was carried out using differential scanning calorimetry and fourier transform infrared spectroscopy. In situ gel formulations were prepared with pluronic F127 (PF127), a thermosensitive polymer, and chitosan (CH), a natural, biodegradable, and mucoadhesive hydrophilic polymer. In situ gel characteristics such as pH, clarity, gelation temperature, and viscosity were determined.

Results: When the solubility diagrams were examined, it was concluded that SBE-β-CD showed a linear increase, therefore, AL-type diagram was selected. The formulations were produced using different amounts of PF127 and a fixed ratio of CH. Three in situ gels were evaluated for their pH, gelling temperature, and the rheological behaviors, and one formulation was selected. It was observed that the formulations had a pH between 6-6.1, and their gelation temperature decreased with increasing PF127 that was between 20°C to 34°C. For the selected formulation (formulation E3), 0.5% rutin and rutin/SBE-β-CD were transferred to the in situ gelling system. Because of in vitro release studies, it was observed that the release of the rutin/SBE-β-CD inclusion complex containing NZ formulation showed a higher burst effect than the others and the release continued for 6 hours.

Conclusion: The results indicated that the combination of PF127 and CH can be a hopeful in situ gelling vehicle for dermal delivery of rutin and rutin/SBE-β-CD.

Keywords: Rutin; SBE-β-cyclodextrin; dermal drug delivery systems; in situ gel; pluronic.